Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer

NCT07346807 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Tongue Squamous Cell Carcinoma

Interventions

PROCEDURE: Lingual Nerve Disruption
DRUG: Tislelizumab
DRUG: Albumin-bound Paclitaxel
PROCEDURE: Cisplatin
PROCEDURE: Peripheral Blood Collection for Immune Monitoring
OTHER: Pain and Quality of Life Assessment

Sponsor

Shanghai Zhongshan Hospital